Stock Events

AMGEN 

$330.83
2732
+$5.74+1.77% Friday 20:00

Statistics

Day High
333.85
Day Low
326
52W High
333.85
52W Low
212.66
Volume
2,191,328
Avg. Volume
2,399,106
Mkt Cap
177.47B
P/E Ratio
47.26
Dividend Yield
2.72%
Dividend
9

Upcoming

Dividends

2.72%Dividend Yield
10Y Growth
13.94%
5Y Growth
9.18%
3Y Growth
8.53%
1Y Growth
5.63%

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
3.83
4.22
4.61
5
Expected EPS
3.89
Actual EPS
3.96

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMGN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences competes in the biopharmaceutical sector focusing on antiviral drugs, similar therapeutic areas as Amgen.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie operates in the same biopharmaceutical space, with a strong presence in immunology and oncology, directly competing with Amgen's product lines.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb is a major player in the biopharmaceutical industry, with a focus on cancer and immune system disorders, overlapping with Amgen's market.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is a global pharmaceutical company with a broad range of products that compete across several of Amgen's key therapeutic areas.
Merck &
MRK
Mkt Cap323.59B
Merck & Co. focuses on pharmaceuticals including oncology, vaccines, and animal health, competing with Amgen in the oncology and biologic drugs market.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the immunology and oncology sectors, similar to Amgen.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals specializes in biopharmaceuticals, particularly in monoclonal antibodies, a direct competitor to Amgen's biologic treatments.
Novartis
NVS
Mkt Cap244.62B
Novartis is a global healthcare company that competes with Amgen in several areas, including biopharmaceuticals and generic drugs.
Rogers
ROG
Mkt Cap2.22B
Roche Holding AG, with its strong focus on oncology and immunotherapy, competes directly with Amgen in the biopharmaceutical and diagnostics sectors.
Sanofi
SNY
Mkt Cap130B
Sanofi operates globally in the pharmaceutical sector, with a focus on diabetes, oncology, and rare diseases, areas where Amgen also has significant interests.

Analyst Ratings

322.91$Average Price Target
The highest estimate is $360.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
62%
Hold
38%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Show more...
CEO
Robert Bradway
Employees
26700
Country
US
ISIN
US0311621009
WKN
000867900

Listings